Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Net Income (2016 - 2025)

Historic Net Income for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$62.8 million.

  • Ascendis Pharma A's Net Income rose 4110.4% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 4700.19%. This contributed to the annual value of -$398.7 million for FY2024, which is 2302.61% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Net Income is -$62.8 million, which was up 4110.4% from -$35.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Net Income registered a high of -$35.3 million during Q2 2025, and its lowest value of -$200.7 million during Q4 2022.
  • Moreover, its 5-year median value for Net Income was -$117.3 million (2024), whereas its average is -$113.5 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 8596.18% in 2022, then soared by 6993.03% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Net Income stood at -$121.3 million in 2021, then tumbled by 65.42% to -$200.7 million in 2022, then soared by 59.64% to -$81.0 million in 2023, then skyrocketed by 52.12% to -$38.8 million in 2024, then plummeted by 62.01% to -$62.8 million in 2025.
  • Its last three reported values are -$62.8 million in Q3 2025, -$35.3 million for Q2 2025, and -$97.3 million during Q1 2025.